BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8457783)

  • 1. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units.
    Marshall MV; Marshall MH; Degen DR; Roodman GD; Kuhn JG; Ross ME; Von Hoff DD
    Stem Cells; 1993 Jan; 11(1):62-9. PubMed ID: 8457783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line.
    Pacheco DY; Stratton NK; Gibson NW
    Cancer Res; 1989 Sep; 49(18):5108-10. PubMed ID: 2766282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of toxicity of hepsulfam in human tumor cell lines.
    Pacheco DY; Cook C; Hincks JR; Gibson NW
    Cancer Res; 1990 Dec; 50(23):7555-8. PubMed ID: 2253204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance.
    Armstrong DK; Gordon GB; Hilton J; Streeper RT; Colvin OM; Davidson NE
    Cancer Res; 1992 Mar; 52(6):1416-21. PubMed ID: 1540950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients.
    Hincks JR; Adlakha A; Cook CA; Johnson CS; Furmanski P; Gibson NW
    Cancer Res; 1990 Dec; 50(23):7559-63. PubMed ID: 2253205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow.
    Berger DP; Winterhalter BR; Dengler WA; Fiebig HH
    Anticancer Drugs; 1992 Oct; 3(5):531-9. PubMed ID: 1450448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of oxaliplatin against human tumor colony-forming units.
    Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD
    Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
    Hendricks CB; Grochow LB; Rowinsky EK; Forastiere AA; McGuire WP; Ettinger DS; Sartorius S; Lubejko B; Donehower RC
    Cancer Res; 1991 Nov; 51(21):5781-5. PubMed ID: 1933848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro.
    Ajani JA; Blaauw AA; Spitzer G; Baker FL; Tomasovic B; Umbach G; Thielvoldt D; Zander AR; Dicke KA
    Exp Hematol; 1985; 13 Suppl 16():95-100. PubMed ID: 2580731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
    Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
    Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
    Rha SY; Izbicka E; Lawrence R; Davidson K; Sun D; Moyer MP; Roodman GD; Hurley L; Von Hoff D
    Clin Cancer Res; 2000 Mar; 6(3):987-93. PubMed ID: 10741725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation.
    Chlebowski RT; Dietrich M; Akman S; Block JB
    Cancer Treat Rep; 1985 May; 69(5):527-32. PubMed ID: 4005875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay.
    Durie BG; Soehnlen B; Prudden JF
    J Biol Response Mod; 1985 Dec; 4(6):590-5. PubMed ID: 4087032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a radiometric system to screen for antineoplastic agents: correlation with a human tumor cloning system.
    Von Hoff DD; Forseth B; Warfel LE
    Cancer Res; 1985 Sep; 45(9):4032-8. PubMed ID: 3928148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
    Bieber MM; Twist CJ; Bhat NM; Teng NN
    Pediatr Blood Cancer; 2007 Apr; 48(4):380-6. PubMed ID: 16421902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of a human tumor colony-forming assay to new drug screening.
    Shoemaker RH; Wolpert-DeFilippes MK; Kern DH; Lieber MM; Makuch RW; Melnick NR; Miller WT; Salmon SE; Simon RM; Venditti JM
    Cancer Res; 1985 May; 45(5):2145-53. PubMed ID: 3986767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cytotoxicity of methyl protoneogracillin (NSC-698793) and gracillin (NSC-698787), two steroidal saponins from the rhizomes of Dioscorea collettii var. hypoglauca, against human cancer cells in vitro.
    Hu K; Yao X
    Phytother Res; 2003 Jun; 17(6):620-6. PubMed ID: 12820229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of dimethylaminosulfonates of alkane diols as a novel group of anticancer agents.
    Sanyal U; Nanda R; Samanta S; Pain A; Dutta S; Verma AS; Rider BJ; Agrawal KC
    Cancer Lett; 2000 Jul; 155(1):89-97. PubMed ID: 10814884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.